Literature DB >> 21593766

Blocking MAPK signaling downregulates CCL21 in lymphatic endothelial cells and impairs contact hypersensitivity responses.

Tomomitsu Miyagaki1, Makoto Sugaya, Hitoshi Okochi, Yoshihide Asano, Yayoi Tada, Takafumi Kadono, Andrew Blauvelt, Kunihiko Tamaki, Shinichi Sato.   

Abstract

CCL21 expression by lymphatic endothelial cells (LECs) is essential for migration of CCR7+ immune cells from skin to regional lymph nodes (LNs). We investigated the importance of mitogen-activated protein kinase (MAPK) signaling in CCL21 expression by ECs in vitro and in vivo. Normal human dermal lymphatic microvascular ECs (HMVEC-dLy) stimulated in vitro with oncostatin M (OSM) expressed high amounts of CCL21 mRNA. CCL21 protein expression by HMVEC-dLy was also markedly increased by OSM compared with unstimulated cultures. Marked phosphorylation of MAPK 44/42 was detected in HMVEC-dLy stimulated by OSM. CCL21 expression by HMVEC-dLy was blocked by a JAK inhibitor 1, JAK3 inhibitor, and U0126 (a MAPK kinase inhibitor) in vitro, all of which blocked phosphorylation of MAPK 44/42. In addition, injection of U0126 into murine skin significantly decreased CCL21 mRNA and protein expression. Moreover, injection of U0126 before sensitization decreased migration of dendritic cells to draining LNs and decreased contact hypersensitivity responses. In summary, these results suggest that the MAPK pathway is important for CCL21 expression by LECs in vitro and in vivo. Blocking MAPK signaling within skin may offer a novel approach to treatment of inflammatory skin diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593766     DOI: 10.1038/jid.2011.135

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

Authors:  B Schilling; W Sondermann; F Zhao; K G Griewank; E Livingstone; A Sucker; H Zelba; B Weide; U Trefzer; T Wilhelm; C Loquai; C Berking; J Hassel; K C Kähler; J Utikal; P Al Ghazal; R Gutzmer; S M Goldinger; L Zimmer; A Paschen; U Hillen; D Schadendorf
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

2.  Inhibition of TGFBIp expression reduces lymphangiogenesis and tumor metastasis.

Authors:  Y-S Maeng; B Aguilar; S-I Choi; E K Kim
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

3.  Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers.

Authors:  Erica M Pimenta; Betsy J Barnes
Journal:  Cancers (Basel)       Date:  2014-04-23       Impact factor: 6.639

4.  Mesenteric Lymphatic Alterations Observed During DSS Induced Intestinal Inflammation Are Driven in a TLR4-PAMP/DAMP Discriminative Manner.

Authors:  Matthew Stephens; Shan Liao; Pierre-Yves von der Weid
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

Review 5.  New Insights of CCR7 Signaling in Dendritic Cell Migration and Inflammatory Diseases.

Authors:  Wenxiang Hong; Bo Yang; Qiaojun He; Jiajia Wang; Qinjie Weng
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.